Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
The purpose of this study is to determine if self-administered oral resveratrol can dampen
 joint pain for individuals with pseudoachondroplasia compared to placebo.
Inclusion Criteria:

 -  The diagnosis of pseudoachondroplasia is based on clinical assessment either in person
 or by photographic review by skeletal dysplasia specialist (JTH),

 -  Healthy beyond pseudoachondroplasia associated complications,

 Exclusion Criteria:

 -  Current use of resveratrol

 -  Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine
 and triazolam.

 -  Other non-pseudoachondroplasia related health conditions, e.g. cancers.

 -  Pregnancy or breastfeeding. Women must use adequate contraception during the study.

 -  Participation in another clinical study and/or using investigational agents.

 -  Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.

 -  Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine,
 Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir,
 Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine,
 Fosphenytoin, Phenytoin or Warfarin.

 -  Baseline level of pain of 2 or higher on 10 point scale.

 -  Platelet count below 50,000 per ul on baseline complete blood count (CBC).